###begin article-title 0
###xml 64 67 64 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
Inhibition of retinal neovascularization by siRNA targeting VEGF165
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 81 84 81 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 128 134 128 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 154 157 154 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 227 233 <span type="species:ncbi:10090">murine</span>
To investigate whether vector-based vascular endothelial growth factor 165 (VEGF)165 targeted siRNA expression system (pSilencersiVEGF) could inhibit VEGF165 expression in vitro and suppresses retinal neovascularization in the murine model of oxygen-induced retinopathy.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 9 15 9 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 48 51 48 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 266 272 266 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 462 465 462 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 500 503 500 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 490 495 <span type="species:ncbi:9606">human</span>
###xml 507 513 <span type="species:ncbi:10090">murine</span>
pSilencersiVEGF, from which siRNA targeting VEGF165 could be generated, was constructed and transfected to human umbilical vein endothelial cells. Then the level of VEGF isoforms in cultured cells was measured by RT-PCR and ELISA. Intravitreal injection of pSilencersiVEGF was performed in mice with ischemic retinopathy. Retinal neovascularization was evaluated by angiography using fluorescein-labeled dextran and quantitated histologically. The levels of VEGF164, which is equivalent to human VEGF165 in murine retinas were determined by RT-PCR and western immunoblotting.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 18 21 18 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 74 80 74 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 158 161 158 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">189</sub>
###xml 170 173 170 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 241 247 241 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 375 381 375 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 460 463 460 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 521 527 521 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 478 484 <span type="species:ncbi:10090">murine</span>
Expression of VEGF165 in cultured cells was greatly curtailed by pSilencersiVEGF under both normoxia and hypoxia conditions. However, the other isoforms, VEGF189 and VEGF121, were expressed to a similar degree regardless of whether pSilencersiVEGF was administered. Based on angiography and histological analysis, retinal neovascularization in the eyes treated with pSilencersiVEGF were significantly reduced compared to the control eyes. Furthermore, the VEGF164 levels in the murine retinas were suppressed by pSilencersiVEGF.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 88 94 88 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 118 121 118 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 154 160 154 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 34 40 <span type="species:ncbi:10090">murine</span>
Retinal neovascularization in the murine model was significantly attenuated by pSilencersiVEGF through decreasing VEGF164 levels in the retinas. pSilencersiVEGF seems to be a potential therapeutic tool for ischemic-induced retinal diseases.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
Retinal neovascularization, abnormal formation of new vessels from preexisting capillaries in the retina, is a common complication of many ocular diseases, such as advanced diabetic retinopathy, and retinopathy of prematurity. Neovascularization can lead to fibrosis and disruption of delicate tissues required for vision. Laser photocoagulation as conventional treatment is effective in halting the progression of angiogenesis in the short-term. However, it is also destructive to the retinal tissue, leads to immediate and sometimes significant loss of vision, and does not address the underlying angiogenic mechanisms of the disease. Therefore, therapy targeting molecular mechanisms underlying retinal neovascularization may provide better treatment result and fewer detrimental side effect.
###end p 11
###begin p 12
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 816 817 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
Angiogenesis is a complex process, involving multiple gene products expressed by different cell types, all contributing to an integrated sequence of events. However, laboratory studies have demonstrated that vascular endothelial growth factor (VEGF) plays a central role in several retinal vascular diseases. Clinical trials have confirmed the importance of VEGF in disease pathogenesis [1,2]. Consequently, VEGF becomes an optimal target for inhibition of retinal neovascularization. Accumulated data indicate that attenuation of VEGF activity could effectively suppress retinal neovascularization. Recent treatments based on antibody technology have been proven to be efficacious. Lucentis, a anti-VEGF antibody fragment, has been approved as an antiangiogenic drug for the treatment of ocular neovascularization [3]. Although antibodies are effective, they are not efficient. Large amounts of antibodies are needed to suppress the targeted protein, and the inhibitory effects of antibodies are transient unless these high doses are administered repeatedly.
###end p 12
###begin p 13
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 666 667 666 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 1022 1025 1022 1025 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 1031 1034 1031 1034 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">145</sub>
###xml 1040 1043 1040 1043 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1049 1052 1049 1052 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">189</sub>
###xml 1062 1065 1062 1065 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">206</sub>
###xml 1067 1068 1067 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 1218 1221 1218 1221 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1229 1232 1229 1232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1263 1266 1263 1266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1272 1275 1272 1275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1339 1340 1339 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 1355 1358 1355 1358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1528 1531 1528 1531 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 985 990 <span type="species:ncbi:9606">human</span>
###xml 1131 1137 <span type="species:ncbi:10090">murine</span>
###xml 1181 1187 <span type="species:ncbi:10090">murine</span>
###xml 1208 1213 <span type="species:ncbi:9606">human</span>
RNA interference (RNAi) is a recently developed technique to silence proteins in a sequence-specific manner by inhibiting mRNA and consequently reducing protein expression. The high efficiency and specificity of RNAi has made it a powerful and widely used tool for gene therapy. The functional mediator of RNAi is a short double strand RNA (dsRNA) oligonucleotide called small interfering RNA (siRNA) [4]. A growing number of investigations are examining the use of siRNA as a candidate therapeutic agent, Currently, there are two siRNA-based molecules: Cand5, which is a siRNA against all isoforms of VEGF, and siRNA-027, a kind of siRNA targeting VEGF receptor 1 [5]. Acuity Pharmaceuticals (Philadelphia, PA) has begun a Phase II clinical trial for Cand5, and Sirna Therapeutics (San Francisco, CA) is on a Phase 1 clinical trial for siRNA-027. However, due to differential pre-mRNA splicing, a single VEGF gene gives rise to many different VEGF isoforms. To date, five isoforms of human VEGF have been identified: VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206 [6]. Although VEGF is highly conserved throughout evolution, the murine homologs contain one fewer amino acid. The murine designation for the human VEGF165 is VEGF164. Of the various isoforms, VEGF165 (VEGF164) appears to be the major pathological VEGF isoform in the eye [7]. Because VEGF165 is a major disease-causing isoform in models of neovascular eye disease, we expected to identify whether retinal angiogenesis could be attenuated by siRNA targeting VEGF165.
###end p 13
###begin p 14
###xml 173 176 173 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 273 276 273 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 195 201 <span type="species:ncbi:10090">murine</span>
In this report, we used a vector-based siRNA expression system, which overcomes the limitations of transience and high cost in synthetic siRNAs, to specifically inhibit VEGF165 expression in the murine model of proliferative retinopathy. Our data confirm the potential VEGF165 inhibitors for the treatment of ocular angiogenesis.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 21 27 21 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
Recombinant pSilencersiVEGF construction
###end title 16
###begin p 17
###xml 40 43 40 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 658 661 658 661 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
The cDNA oligonucleotides targeting VEGF165 mRNA were designed and examined by Guan et al. [13]. A pair of 63 nucleotide oligos containing endonuclease restriction sites at both ends was synthesized by the Sangong Company (Shanghai, China). The sequences used were: First strand-5'-GAT CCG ATA GAG CAA GAC AAG AAA TTC AAG AGA TTT CTT GTC TTG CTC TAT CTT TTT TGG AAA-3'; Second strand-5'-AGC TTT TCC AAA AAA GAT AGA GCA AGA CAA GAA ATC TTT GAA TTT CTT GTC TTG CTC TAT CG-3' (complementary sequence is indicated in red). The annealed dsDNA oligonucleotides were ligated between the BamHI and HindIII sites on the pSilencer2.1-U6 hygro vector. The targeted VEGF165 sequences were GAT AGA GCA AGA CAA GAA A. All inserted sequences were confirmed by DNA sequencing.
###end p 17
###begin title 18
Cell culture and transfection of cells
###end title 18
###begin p 19
###xml 466 467 459 460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 759 765 750 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 863 864 854 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 952 958 943 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 200 206 <span type="species:ncbi:9913">bovine</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
Human umbilical vein endothelial cell lines (HUVECs) were purchased from the American Type Culture Collection (Manassas, VA). HUVECs were grown in F12K medium, containing 0.1 mg/ml heparin, 20% fetal bovine serum, 0.03 mg/ml endothelial cell growth supplement (BD Biosciences, San Jose, CA), and antibiotic mixtures of 100 U/ml penicillin G and 100 mug/ml streptomycin sulfate. Cells were cultured in an incubator at 37 degreesC in an atmosphere of 95% air and 5% CO2. In the vitro studies, an oxygen concentration of 20% was considered normoxic. Hypoxia was 1% oxygen. In the vivo studies, normoxic mice were raised in room-air-raised. For hyperoxia, mice were kept in 75+/-2% oxygen. Transfection reagent lipofectamine2000 was used to transfer the pSilencersiVEGF to the HUVECs according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). In brief, 2x105 HUVECs cells were seeded into six-well plates. A 2.5:1 ratio of lipofectamine-pSilencersiVEGF (Invitrogen) complexes were prepared and added to the HUVECs.
###end p 19
###begin title 20
Reverse transcription and polymerase chain reaction
###end title 20
###begin p 21
###xml 31 37 <span type="species:ncbi:10090">murine</span>
###xml 904 909 <span type="species:ncbi:9606">human</span>
###xml 1106 1112 <span type="species:ncbi:10090">murine</span>
Whole RNA of cultured cells or murine retinas were isolated with TRIzol(R) reagent (Invitrogen). Total RNA was isolated using Trizol reagents (Gibco-BRL Life Technologies, Gibco, Carlsbad, CA), followed by treatment for 45 min with RNase-free DNase at 37 degreesC (Message Clean; GeneHunter Corp., Nashville, TN), phenol:chloroform (ratio 1:1) extraction, ethanol precipitation, and stabilizing in DEPC-treated water. RNA concentration was determined by spectrophotometric readings at 260 and 280 nm. Each 2 mg of RNA extract was reverse-transcribed into cDNA with RevertAidTM First Strand cDNA Synthesis Kit (MBI, Burlington, MD). PCR was performed in 50 microl of a solution containing Taq DNA polymerase, dNTP, VEGF primer, or beta-actin primer and RT products. The primer pair, 5'-CGA AGT GGT GAA GTT CAT GGA TG-3' (sense) and 5'-TTC TGT ATC AGT CTT TCC TGG TGA G-3' (antisense), was used to amplify human VEGF isoforms in cultured cells. The primer pair, 5'-CCT CCG AAA CCA TGA ACT TTC TGC TC-3' (sense) and 5'-CAG CCT GGC TCA CCG CCT TGG CTT-3' (antisense), was designed to yield the PCR products of murine VEGF isoforms. The primer pair, 5' CGT TGA CAT CCG TAA AGA C 3' (sense) and 5' TGG AAG GTG GAC AGT GAG 3' (antisense), was used to obtain the PCR product of beta-actin. After a preincubation for 5 min at 94 degreesC, 30 cycles of amplification (94 degreesC for 45 s, 60 degreesC for 45 s, and 72 degreesC for 45 s) were performed, and beta-actin was used as an internal control. Amplified products were run in a 1.5% ethidium bromide agarose gel, band intensities were captured with a ChemiDoc system and LabWorks software (UVP, Upland, CA), and values were transferred to an Excel spreadsheet for calculation of means and standard errors.
###end p 21
###begin title 22
ELISA assay for VEGF production
###end title 22
###begin p 23
###xml 215 218 209 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 380 381 374 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
The medium from normoxia and hypoxia cultured cells was collected, centrifuged at 750xg for 5 min, and stored at -70 degreesC. Concurrently, cells were trypsinized and counted. The concentration of the secreted VEGF165 isoform in the media was determined with an ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions and was expressed as pg VEGF/105 cells.
###end p 23
###begin title 24
Animal model of proliferative retinopathy
###end title 24
###begin p 25
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1061 1067 1045 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 126 132 <span type="species:ncbi:10090">murine</span>
###xml 219 223 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 633 637 <span type="species:ncbi:10090">mice</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
###xml 847 851 <span type="species:ncbi:10090">mice</span>
###xml 920 924 <span type="species:ncbi:10090">Mice</span>
###xml 1146 1150 <span type="species:ncbi:10090">mice</span>
###xml 1382 1386 <span type="species:ncbi:10090">mice</span>
The study protocol conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The reproducible murine model of oxygen-induced retinopathy (OIR) has been described previously [8]. C57BL/6J mice were bought from Experimental Animal Center of Central South University, Changsha, Hunan province, China. The mice were exposed to less than 300 lx of 12 h cyclical broad spectrum light. The oxygen-treated mice were housed in an incubator. Oxygen concentration was monitored with a Beckman oxygen analyzer (Model D2; Beckman,. Irvine, CA). The cage temperature was maintained at 23 degreesC+/-2 degreesC. The mice were placed in the oxygen chamber with enough food and water to sustain them for 5 days. Postnatal day 7 (P7) C57BL/6J mice and their nursing mothers were exposed to 75%+/-2% oxygen for five days. On P12, the mice were removed from the chamber and maintained in room air until P17. Mice of the same strain and of the same age were kept in room air and used as control subjects. Intravitreal injections of liposome-pSilencersiVEGF complexes were performed at P12 as described in the next section. At P17, the mice were sacrificed by cardiac perfusion of 4% paraformaldehyde in phosphate-buffered saline (PBS) catalog number of PBS is 20012043 (Gibco), and their eyes were enucleated for RT-PCR and immunohistologic analysis. Alternatively, some mice underwent retinal fluorescein angiography, as described in the next section.
###end p 25
###begin title 26
Intravitreal injections
###end title 26
###begin p 27
###xml 409 415 405 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 471 477 463 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
At P12, mouse pups were deeply anesthetized with a 30 mg/kg intraperitoneal injection of sodium pentobarbital. The lid fissure was opened with a no. 11 scalpel blade, and the eye was proptosed. Intravitreal injections were performed by first entering the eye with an Ethicon TG140-8 suture needle at the posterior limbus. A 32-gauge Hamilton needle and syringe were used to deliver 1 microl liposome-pSilencersiVEGF complex (0.5 microl liposome and 1-1000 ng of pSilencersiVEGF) or 1 microl control complex (0.5 microl liposome and 0.5 microl of 2 mg/ml pSilencer null vector) into the vitreous cavity.
###end p 27
###begin title 28
Angiography with high-molecular-weight fluorescein-dextran
###end title 28
###begin p 29
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
At P17, mice were anesthetized with a 30 mg/kg intraperitoneal injection of sodium pentobarbital sodium, and cardiac perfusion was performed with 1 ml PBS containing 50 mg/ml fluorescein-labeled dextran (2x106 average molecular weight; Sigma, St Louis, MO), clarified by centrifugation for 5 min at 10,600 xg. Subsequently, the mice were sacrificed, and their eyes were enucleated. The retinas were dissected and flatmounted on microscope slides with glycerol gelatin.
###end p 29
###begin title 30
Histological analysis of neovascularization
###end title 30
###begin p 31
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
The eyes of sacrificed P17 mice were enucleated, fixed overnight with 4% paraformaldehyde in PBS, and embedded in paraffin. Half of the group of mice were used for angiography with high-molecular-weight fluorescein-dextran, and the other half were used for histological analysis of neovascularization. Paraffin-embedded axial serial sections of the retina, 6 microm thick, were obtained starting at the optic nerve head. After staining with periodic acid-Schiff reagent and hematoxylin, we evaluated 10 intact sections of equal length, each 30 microm apart, for a span of 300 microm. All retinal vascular cell nuclei anterior to the internal limiting membrane were counted in each section according to a masked protocol. The mean of all ten counted sections yielded average neovascular cell nuclei per 6mum section per eye.
###end p 31
###begin title 32
###xml 37 43 <span type="species:ncbi:10090">murine</span>
Western blot analysis of VEGF in the murine retina
###end title 32
###begin p 33
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 379 382 <span type="species:ncbi:10116">rat</span>
###xml 490 495 <span type="species:ncbi:10090">mouse</span>
The murine retinas were collected and lysed in lysis buffer composed of 150 mmol/l NaCl, 50 mmol/l Tris-HCl, pH 7.4, 2 mmol/l EDTA, and 1% NP-40 that also contained protease inhibitors (Boehringer Mannheim, Mannheim, Germany). Total protein (30 mug per lane) was loaded on SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane and incubated with a 1:500 dilution rat monoclonal anti-VEGF antibody Santa Cruz (Santa Cruz, CA, catalog number sc-80436) and a 1:10,000 dilution mouse monoclonal anti-beta-actin antibody (Sigma, St. Louis, MO), followed by incubation with corresponding secondary antibodies (peroxidase conjugated). The enhanced chemiluminescence (ECL) chemiluminescence reagent was added to the membrane according to the manufacturer's directions. The membrane was exposed to an X-ray film for 1 min before it was developed and fixed. Images of blots were entered into a computer using a scanner (Epson, Nagano, Japan) and analyzed using LabWorks Software (UVP). Then, values were transferred to an Excel spreadsheet for calculation of means and standard errors.
###end p 33
###begin title 34
Statistics
###end title 34
###begin p 35
###xml 132 133 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The results were expressed as mean+/-standard error of mean (SEM). One-way ANOVA followed by the least significant difference (LSD)-t-test were used to evaluate significant differences. A p value <0.05 was considered statistically significant.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
###xml 19 22 19 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 64 70 64 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
Suppression of VEGF165 expression in cultured cells by pSilencersiVEGF
###end title 37
###begin p 38
###xml 38 41 38 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 85 91 85 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 130 133 130 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 159 165 159 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 255 256 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 275 276 275 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 453 462 453 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1A</xref>
###xml 470 473 470 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 498 504 498 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 644 647 644 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 656 659 656 659 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">189</sub>
###xml 726 732 726 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 781 784 781 784 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 873 879 873 879 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 894 903 894 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1C</xref>
###xml 931 937 931 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 970 973 970 973 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
To determine whether vector-based VEGF165 targeted siRNA expression system (pSilencersiVEGF) could suppress the expression of VEGF165, we transfected pSilencersiVEGF plasmid to HUVECs. Then the transfected cells were further cultured under normoxia (20% O2) and hypoxia (1% O2) conditions for 24 h, together with null vector transfected and non-transfected HUVECs (as control). All these cells were later used for RT-PCR and ELISA analysis. As shown in Figure 1A,B, VEGF165 mRNA levels in pSilencersiVEGF transfected cells were dramatically decreased under both normoxic and hypoxic conditions compared to the control cells (p<0.05), while VEGF121 and VEGF189 were expressed to a similar degree regardless of whether pSilencersiVEGF was applied. Correspondingly, the amount of VEGF165 protein secreted into the medium of cultured cells was greatly inhibited after pSilencersiVEGF transfection (Figure 1C), indicating that pSilencersiVEGF could specifically decrease VEGF165 expression in cultured cells without alteration of other VEGF isoforms expression under both normoxia and hypoxia conditions.
###end p 38
###begin p 39
###xml 18 21 18 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 63 69 63 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 69 71 69 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A:</bold>
###xml 169 172 169 172 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 178 181 178 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 191 194 191 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">189</sub>
###xml 279 285 279 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 378 380 378 380 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</bold>
###xml 484 485 481 482 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 491 494 488 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 590 591 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 650 653 647 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 676 679 673 676 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 751 757 748 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 769 772 766 769 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">121</sub>
###xml 781 784 778 781 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">189</sub>
###xml 851 857 848 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
Inhibition of VEGF165 expression in cultured cells by pSilencersiVEGFA: Shown is a gel image of a PCR product of VEGF isoforms. Vascular endothelial growth factor (VEGF)121, VEGF165, and VEGF189 mRNA levels were determined by RT-PCR. The lanes are marked as follows: 1) pSilencersiVEGF-transfected cells; 2) pSilencer null vector-transfected cells; and 3) nontransfected cells. B: The levels of VEGF isoforms were quantitated by densitometry and normalized by beta-actin mRNA levels. C: VEGF165 levels in the conditioned media were measured by ELISA kits and normalized to cell counts (1x105). In a comparison with control cells, hypoxia-induced VEGF165 mRNA and secreted VEGF165 expression were found to be decreased after transfection with pSilencersiVEGF, while VEGF121 and VEGF189 were expressed to a similar degree regardless of whether pSilencersiVEGF was administered. Asterisk indicates p<0.05 compared to the control cells.
###end p 39
###begin title 40
###xml 50 56 50 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
Angiographic evaluation of the effect of pSilencersiVEGF on retinal neovascularization
###end title 40
###begin p 41
###xml 32 38 32 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 580 586 580 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 588 596 588 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 546 551 <span type="species:ncbi:10090">mouse</span>
Injection of liposome -pSilencersiVEGF complexes was performed at P12. Injection of fluorescein-labeled dextran into left ventricle was done at P17, followed by retina flatmount. The retinas of room air-raised mice revealed a normal capillary network without nonperfusion area and neovascular tufts. However, retinas from hyperoxia-exposed mice with pSilencer null vector injection or without any injection contained multiple neovascular tufts and central nonperfusion areas. In contrast, fewer neovascular complexes could be found in retinas of mouse eyes injected with pSilencersiVEGF (Figure 2).
###end p 41
###begin p 42
###xml 48 54 48 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 175 176 175 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 235 236 235 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 487 488 487 488 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 649 650 649 650 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 730 736 730 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 62 68 <span type="species:ncbi:10090">murine</span>
###xml 210 214 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 702 706 <span type="species:ncbi:10090">mice</span>
Angiographic analysis of the effect of pSilencersiVEGF on the murine model of retinal neovascularization. Retinal flatmounts were examined by fluorescein dextran angiography. A: Shown is a retinal flatmount of mice raised in room air. B: In this retinal flatmount of mice exposed to hyperoxia, neovascular tufts appear as hyperfluorescence at the junction between the perfused and the nonperfused area. Arrow points to retinal neovascularization, and star marks an area of nonperfusion. C: In this retinal flatmount of hyperoxia exposed mice injected with pSilencer null vector, retinal neovascularization and nonperfusion area were not attenuated. D: Shown is a retinal flatmount of hyperoxia-exposed mice injected with pSilencersiVEGF. The amount of neovascular tufts was markedly reduced and the area of nonperfusion was diminished.
###end p 42
###begin title 43
Histological analysis of retinal neovascularization
###end title 43
###begin p 44
###xml 394 400 394 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 419 427 419 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 476 482 476 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 707 715 707 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4</xref>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
Neovascularization was assessed histologically by counting the endothelial cell nuclei anterior to the inner limiting membrane. Retinas from hyperoxia-exposed mice with injection of 1000 ng pSilencer null vector or without any injection (OIR model) were found to contain multiple neovascular tufts extending into the vitreous. In contrast, fewer neovascular complexes were observed in pSilencersiVEGF-injected retinas (Figure 3). Administration of 1-1000 ng doses of pSilencersiVEGF resulted in a dose-dependent decrease in endothelial cell nuclei numbers anterior to the inner limiting membrane (i.e., inhibition of retinal neovascularization), with a maximum inhibitory effect of 50% at the 1000 ng dose (Figure 4).
###end p 44
###begin p 45
###xml 64 70 64 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 119 121 119 121 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A:</bold>
###xml 297 299 297 299 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</bold>
###xml 372 378 372 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
Histological analysis of the effects of treatment with pSilencersiVEGF on ischemia-induced retinal neovascularization. A: Postnatal day 17 (P17) retina from the eye of a hypoxic mouse injected with 1000 ng pSilencer null vector. Extensive preretinal neovascular loops are apparent (black arrows). B: P17 retina from the eye of hypoxic mouse injected with 1000 ng pSilencersiVEGF. Preretinal neovascular loops were not as apparent, suggesting that treatment reduced preretinal neovascularization compared with the pSilencer null vector-injected eye. The following abbreviations were used in the figure: interlimiting membrane (ILM), ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL).
###end p 45
###begin p 46
###xml 68 74 68 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 102 108 102 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
Dose-dependent inhibition of retinal neovascularization by pSilencersiVEGF Administration of pSilencersiVEGF at doses 1-1000 ng to hypoxic mice resulted in a dose-dependent inhibition of retinal neovascularization as measured by counting the number of endothelial cell nuclei per section, with a maximum inhibitory effect of 50% at the 1000 ng dose. Asterisk (*) indicates p<0.05 compared to the control eye.
###end p 46
###begin title 47
###xml 18 21 18 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 63 69 63 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 36 42 <span type="species:ncbi:10090">murine</span>
Inhibition of VEGF164 expression in murine retinas by pSilencersiVEGF
###end title 47
###begin p 48
###xml 56 62 56 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 82 85 82 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 341 352 341 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5A,B</xref>
###xml 462 465 462 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 559 565 559 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 579 582 579 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">120</sub>
###xml 591 594 591 594 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sub>
###xml 682 688 682 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 724 730 724 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 762 765 762 765 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 848 851 848 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1042 1053 1042 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5C,D</xref>
###xml 1088 1094 1088 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 104 110 <span type="species:ncbi:10090">murine</span>
###xml 399 405 <span type="species:ncbi:10090">murine</span>
###xml 609 615 <span type="species:ncbi:10090">murine</span>
###xml 894 900 <span type="species:ncbi:10090">murine</span>
###xml 1009 1015 <span type="species:ncbi:10090">murine</span>
###xml 1153 1159 <span type="species:ncbi:10090">murine</span>
To determine whether intravitreal injection of pSilencersiVEGF could decrease VEGF164 expression in the murine retinas, we extracted retinas and assessed them by RT-PCR and immunohistochemical analysis. Some retinas were used for RNA extraction and RT-PCR analysis, the others were embedded in paraffin and examined by immunohistochemistry. Figure 5A,B show the PCR products of VEGF isoforms in the murine retinas. Compared to the control eyes, the level of VEGF164 mRNA was significantly downregulated in the retinas of hypoxic animals treated with pSilencersiVEGF, whereas VEGF120 and VEGF188 levels in the murine retinas remained unchanged after local administration of pSilencersiVEGF. To confirm the effect of pSilencersiVEGF on the expression level of VEGF164 at the protein level, we performed immunohistochemical studies to investigate VEGF164 expression patterns in the retinas of the murine model of OIR. We performed western immunoblotting to assess the VEGF164 protein level in the retinas of the murine model of OIR. As shown in Figure 5C,D, local administration of pSilencersiVEGF significantly decreased expression of VEGF protein in the murine retinas.
###end p 48
###begin p 49
###xml 91 98 91 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF.</sup>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 349 350 349 350 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 356 359 356 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">120</sub>
###xml 365 368 365 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 378 381 378 381 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sub>
###xml 441 444 441 444 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 532 538 532 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 552 555 552 555 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">120</sub>
###xml 564 567 564 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">188</sub>
###xml 697 703 697 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 820 822 820 822 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B:</bold>
###xml 898 899 895 896 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 938 941 935 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 997 1000 994 997 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 1056 1062 1053 1059 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 1110 1111 1107 1108 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1198 1200 1195 1197 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D:</bold>
###xml 1219 1222 1216 1219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1385 1386 1377 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 64 70 <span type="species:ncbi:10090">murine</span>
###xml 99 105 <span type="species:ncbi:10090">Murine</span>
###xml 397 403 <span type="species:ncbi:10090">murine</span>
###xml 453 459 <span type="species:ncbi:10090">murine</span>
###xml 578 584 <span type="species:ncbi:10090">murine</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
###xml 670 676 <span type="species:ncbi:10090">murine</span>
###xml 718 724 <span type="species:ncbi:10090">murine</span>
###xml 776 782 <span type="species:ncbi:10090">murine</span>
###xml 957 963 <span type="species:ncbi:10090">murine</span>
###xml 1017 1023 <span type="species:ncbi:10090">murine</span>
Suppression of vascular endothelial growth factor expression in murine retinas by pSilencersiVEGF. Murine retinas were extracted and examined for VEGF level. One-way ANOVA followed by the LSD-t-test were used to evaluate significant differences. A p value <0.05 was considered statistically significant. Error bars are standard error of mean (SEM). A: VEGF120, VEGF164, and VEGF188 mRNA levels in murine retinas were examined by RT-PCR. VEGF164 mRNA in murine retinas was downregulated after intravitreal administration of pSilencersiVEGF, whereas VEGF120 and VEGF188 levels in murine retinas remained unchanged. Lanes are marked as follows: 1) room air-raised mice; 2) murine model with pSilencersiVEGF injection; 3) murine model with pSilencer null vector injection; and 4) murine model of oxygen-induced retinopathy. B: Relative VEGF isoforms mRNA quantification was related to beta-actin mRNA. C: Shown is an immunoblot assay for VEGF165 protein in the murine retinas. The total amount of VEGF164 immunosignal in murine retinas was reduced by pSilencersiVEGF. The following abbreviations are used in panel C: ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL). D: The levels of VEGF165 were quantitated by densitometry and normalized to beta-actin protein levels. Data are expressed as mean+/-SEM and were analyzed by one-way ANOVA followed by LSD-t-test. The means of groups 3 and 4 are statistically greater than the means of groups 1 and 2 (p<0.05).
###end p 49
###begin title 50
Discussion
###end title 50
###begin p 51
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 596 599 596 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 605 608 605 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 697 700 697 700 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 839 842 839 842 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 963 966 963 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
Vascular homeostasis is regulated by two counter-balancing systems: angiogenic stimulators and angiogenic inhibitors [9,10]. Under pathological conditions, such as diabetic retinopathy and retinopathy of prematurity, the retina increases the production of angiogenic stimulators and reduces the production of angiogenic inhibitors, which would disrupt the balance between the positive and negative regulators of angiogenesis [9]. VEGF as major angiogenic stimulator is upregulated in ocular neovascular diseases [11]. However, due to alternative splicing of mRNA, VEGF has multiple isoforms. VEGF165 (VEGF164 in mice) is the major disease-causing isoform in models of neovascular eye disease. VEGF165 was found to be more potent than other VEGF isoforms in inducing vascular leakage and breakdown of blood-retinal barrier [12]. Hence, VEGF165 was selected for this study as a target for suppressing retinal neovascularization. We hoped that therapy targeting VEGF165 in the retina could increase specificity and efficacy of the treatment.
###end p 51
###begin p 52
###xml 29 32 29 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 81 84 81 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 128 134 128 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 162 168 162 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 212 215 212 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 490 496 490 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 547 550 547 550 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 764 770 764 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 893 899 893 899 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 674 680 <span type="species:ncbi:10090">murine</span>
###xml 903 908 <span type="species:ncbi:9606">human</span>
To decrease pathological VEGF165 upregulation, we constructed a vector-based VEGF165 targeted siRNA expression system (pSilencersiVEGF) for our studies. pSilencersiVEGF has been shown to specifically inhibit VEGF165 expression in normoxia-cultured tumor cells [13]. It has been hypothesized that sustained overproduction of VEGF by hypoxia retinal cells promotes retinal neovascularization in several neovascular eye diseases [1]. Consequently, close attention was paid to whether pSilencersiVEGF could work properly under hypoxia conditions. VEGF165 was found to be decreased dramatically not only in the hypoxia cultured cells but also in the hypoxia retinal cells in the murine animal models, suggesting that hypoxia-induced VEGF could be abrogated by pSilencersiVEGF under hypoxia conditions. We surmise that overproduction of VEGF by hypoxia retinal cells may also be blocked by pSilencersiVEGF in human neovascular eye diseases such as diabetic retinopathy.
###end p 52
###begin p 53
###xml 114 120 114 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 348 351 348 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">164</sub>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 793 795 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 847 853 847 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 1075 1078 1075 1078 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1163 1166 1163 1166 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1296 1299 1296 1299 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1371 1372 1371 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 1466 1469 1466 1469 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1560 1563 1560 1563 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 1611 1617 1611 1617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 1803 1805 1803 1805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 56 62 <span type="species:ncbi:10090">murine</span>
###xml 380 386 <span type="species:ncbi:10090">murine</span>
In the current study, retinal neovascularization in the murine model was greatly inhibited by 1000 ng of pSilencersiVEGF. This dramatic decrease in retinal neovascularization could be attributed to the following reasons. First, the localization of plasmids mediated by cationic liposome is close to the site of hypoxia-induced VEGF generation. VEGF164 level in the retinas of the murine model was found to increase in the inner nuclear layer and ganglion cell layer in this study, which was consistent with a previous study [14]. However, cationic liposome has been confirmed as an effective reagent for retinal gene transfer, which could carry plasmids into retinal ganglion cells and retinal pigment epithelial cells through the injection of plasmids and liposome complex into the vitreous [15]. Accordingly, intravitreal injections of pSilencersiVEGF could be successfully carried into retinal cells, which are in charge of producing hypoxia-induced VEGF by liposome. Second, the catalytic nature of RNAi entered the retinal cells. Small hairpin RNA (shRNA) targeting VEGF165 could be generated and processed into siRNA in these cells. The siRNA targeting VEGF165 binds to the RNA induced silencing complex (RISC), which in turn becomes activated. The activated RISC complex seeks out the VEGF165 mRNA and then splices the mRNA at the site of the homologous sequence [4]. Furthermore, in multiple turnover kinetic fashion, the activated RISC can seek another VEGF165 mRNA to bind and destroy. One activated RISC complex can bind and destroy hundreds of VEGF165 mRNA. Finally, the high efficiency of pSilencersiVEGF is attributed to the divisional rate of the retinal cells. The division rate of cells that have taken in siRNA is an important factor when determining durability of silencing in cells [16], which leads to dilution of the activated RISC as it is divided between daughter cells. Because the division rate of retinal cells is slow, the silencing effect in the cells could last until upregulation of VEGF in ischemic retina disappears.
###end p 53
###begin p 54
###xml 46 49 46 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 74 80 74 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 100 103 100 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">165</sub>
###xml 328 334 328 334 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">siVEGF</sup>
###xml 167 173 <span type="species:ncbi:10090">murine</span>
In summary, we found that siRNA targeting VEGF165 expressed from pSilencersiVEGF could decrease VEGF165 expression in vitro and reduce retinal neovascularization in a murine model of OIR. However, further experiments are necessary to determine whether detrimental side effects will appear after local administration of pSilencersiVEGF.
###end p 54
###begin title 55
Acknowledgments
###end title 55
###begin p 56
This research was supported by National Natural Science Foundation of China.
###end p 56
###begin title 57
References
###end title 57
###begin article-title 58
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.
###end article-title 58
###begin article-title 59
Vascular endothelial growth factor (VEGF) and its effect on angiogenesis.
###end article-title 59
###begin article-title 60
MARINA Study GroupSubgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
###end article-title 60
###begin article-title 61
RNAinterference is mediated by 21- and 22-nucleotide RNAs.
###end article-title 61
###begin article-title 62
Firm sets sights on gene silencing to protect vision.
###end article-title 62
###begin article-title 63
Vascular endothelial growth factor.
###end article-title 63
###begin article-title 64
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.
###end article-title 64
###begin article-title 65
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Oxygen-induced retinopathy in the mouse.
###end article-title 65
###begin article-title 66
Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy.
###end article-title 66
###begin article-title 67
Molecular mechanisms of blood vessel formation.
###end article-title 67
###begin article-title 68
Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.
###end article-title 68
###begin article-title 69
VEGF function in vascular pathogenesis
###end article-title 69
###begin article-title 70
###xml 116 121 <span type="species:ncbi:10090">Mouse</span>
A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing's Sarcoma Growth in a Xenograft Mouse Model.
###end article-title 70
###begin article-title 71
Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression.
###end article-title 71
###begin article-title 72
Gene transfer with the intraocular tissues by different routes of administration.
###end article-title 72
###begin article-title 73
Killing the messenger:short RNAs that silence gene expression.
###end article-title 73

